Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Apr 08, 2022 3:51pm
131 Views
Post# 34589065

RE:RE:RE:RE:RE:RE:RE:RE:RE:New PR

RE:RE:RE:RE:RE:RE:RE:RE:RE:New PR

The abstracts were submitted awhile back. The R&D behind these posters has probably been ongoing for a year or more. You think if the half dozen to a dozen patients who've had high doses of th1902 haven't shown a response that they would pull these posters from the conference? Of course not! None of this has anything to do with how the Ph1 trial is progressing. Like every other biotech they will be positive about an active program and support it right up to the day it gets dropped (if there is such a day).

jfm1330 wrote: It would be strange to have this PR out with positive comments by Marsolais and absolutely no sign of efficacy in phase Ia while it is close to be completed. I know they would be able to hide behind the excuse that phase Ia is not designed to show efficacy, but it would be surprising given that they are still pushing preclinical data pointing at efficacy against very advanced and resistant cancers involving cancer stem cells.
 

longterm56 wrote:
Biobob wrote: Great news for Minimouse... 


Man .. this crowd is getting ugly!!  Hang on, all, we haven't yet heard from those who really know!!!! 

   -LT
 




<< Previous
Bullboard Posts
Next >>